Table Info

Table 3.

A comprehensive list of ongoing oncology clinical trials involving IL-13

Cytokine	Clinical trial ID	Phase	Number of patients	Cancer type	Treatment	Status	Estimated study completion date
IL-13	NCT02208362	I	82	Recurrent or refractory glioma	IL-13Rα2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/truncated CD19-expressing autologous T cells	Active	June 2023
IL-13	NCT04119024	I	24	Melanoma	IL-13Rα2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/truncated CD19-expressing autologous naive and memory T cells plus cyclophosphamide, fludarabine, and IL-2	Recruiting	October 2025
IL-13	NCT04661384	I	30	Ependymoma, glioblastoma, medulloblastoma, leptomeninges cancer	IL-13Rα2-specific Hinge-optimized 4-1BB-co-stimulatory CAR truncated CD19-expressing autologous T-lymphocytes	Recruiting	November 2025
IL-13	NCT04510051	I	18	Brain cancer	IL-13Rα2-specific Hinge-optimized 4-1BB-co-stimulatory CAR truncated CD19-expressing autologous T-lymphocytes plus cyclophosphamide and fludarabine	Recruiting	September 2023
IL-13	NCT04003649	I	60	Recurrent or refractory glioblastoma	IL-13Rα2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/truncated CD19-expressing autologous naive and memory T cells plus ipilimumab and nivolumab	Recruiting	December 2024
IL-13	NCT05168423	I	18	Glioblastoma	CAR-T-EGFR-IL-13Rα2 plus cyclophosphamide and fludarabine	Not yet recruiting	December 2039

EGFR: epidermal growth factor receptor

Declarations

Author contributions

EJ: Conceptualization, Methodology, Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that he has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of materials and data

Not applicable.

Funding

Not applicable.

Copyright

References

GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–544. Erratum in: Lancet. 2017;389:E1. [DOI] [PubMed] [PMC]

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118:9–16. [DOI] [PubMed] [PMC]

Hunter P. The fourth pillar. EMBO Rep. 2017;18:1889–92. [DOI]

Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801. [DOI] [PubMed] [PMC]

Stenken JA, Poschenrieder AJ. Bioanalytical chemistry of cytokines–a review. Anal Chim Acta. 2015;853:95–115. [DOI] [PubMed] [PMC]

Annunziato F, Romagnani C, Romagnani S. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol. 2015;135:626–35. [DOI] [PubMed]

Walker JA, McKenzie ANJ. Development and function of group 2 innate lymphoid cells. Curr Opin Immunol. 2013;25:148–55. [DOI] [PubMed] [PMC]

Ribatti D. The concept of immune surveillance against tumors: the first theories. Oncotarget. 2017;8:7175–80. [DOI] [PubMed] [PMC]

10.

Kartikasari AER, Huertas CS, Mitchell A, Plebanski M. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142. [DOI] [PubMed] [PMC]

11.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. [DOI] [PubMed]

12.

Muhammad Yusoff F, Wong KK, Mohd Redzwan N. Th1, Th2, and Th17 cytokines in systemic lupus erythematosus. Autoimmunity. 2020;53:8–20. [DOI] [PubMed]

13.

Walker JA, Barlow JL, McKenzie AN. Innate lymphoid cells — how did we miss them? Nat Rev Immunol. 2013;13:75–87. [DOI] [PubMed]

14.

Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev. 1996;9:532–62. [DOI] [PubMed] [PMC]

15.

Rodriguez-Rodriguez N, Gogoi M, McKenzie ANJ. Group 2 innate lymphoid cells: team players in regulating asthma. Annu Rev Immunol. 2021;39:167–98. [DOI] [PubMed] [PMC]

16.

Gieseck RL 3rd, Wilson MS, Wynn TA. Type 2 immunity in tissue repair and fibrosis. Nat Rev Immunol. 2018;18:62–76. [DOI] [PubMed]

17.

Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens. 2007;70:1–11. [DOI] [PubMed]

18.

Ikeda H, Chamoto K, Tsuji T, Suzuki Y, Wakita D, Takeshima T, et al. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci. 2004;95:697–703. [DOI] [PubMed]

19.

Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28:4531–8. [DOI] [PubMed] [PMC]

20.

Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27:5944–51. [DOI] [PubMed]

21.

Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–4. [DOI] [PubMed]

22.

Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29:610–8. [DOI] [PubMed]

23.

Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010;29:1093–102. [DOI]

24.

Jou E, Rodriguez-Rodriguez N, Ferreira AF, Jolin HE, Clark PA, Sawmynaden K, et al. An innate IL-25–ILC2–MDSC axis creates a cancer-permissive microenvironment for Apc mutation–driven intestinal tumorigenesis. Sci Immunol. 2022;7:eabn0175. [DOI] [PubMed] [PMC]

25.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99. [DOI] [PubMed] [PMC]

26.

Liu M, Kuo F, Capistrano KJ, Kang D, Nixon BG, Shi W, et al. TGF-β suppresses type 2 immunity to cancer. Nature. 2020;587:115–20. [DOI] [PubMed] [PMC]

27.

Lorvik KB, Hammarström C, Fauskanger M, Haabeth OA, Zangani M, Haraldsen G, et al. Adoptive transfer of tumor-specific Th2 cells eradicates tumors by triggering an in situ inflammatory immune response. Cancer Res. 2016;76:6864–76. [DOI] [PubMed]

28.

Mojic M, Takeda K, Hayakawa Y. The dark side of IFN-γ: its role in promoting cancer immunoevasion. Int J Mol Sci. 2017;19:89. [DOI] [PubMed] [PMC]

29.

Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18:121–6. [DOI] [PubMed] [PMC]

30.

Fournié JJ, Poupot M. The pro-tumorigenic IL-33 involved in antitumor immunity: a yin and yang cytokine. Front Immunol. 2018;9:2506. [DOI] [PubMed] [PMC]

31.

Jou E, Rodriguez-Rodriguez N, McKenzie ANJ. Emerging roles for IL-25 and IL-33 in colorectal cancer tumorigenesis. Front Immunol. 2022;13:981479. [DOI] [PubMed] [PMC]

32.

Shen J, Xiao Z, Zhao Q, Li M, Wu X, Zhang L, et al. Anti-cancer therapy with TNFα and IFNγ: a comprehensive review. Cell Prolif. 2018;51:e12441. [DOI] [PubMed] [PMC]

33.

Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847. [DOI] [PubMed] [PMC]

34.

Djuretic IM, Levanon D, Negreanu V, Groner Y, Rao A, Ansel KM. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol. 2007;8:145–53. [DOI] [PubMed]

35.

Prochazkova J, Pokorna K, Holan V. IL-12 inhibits the TGF-β-dependent T cell developmental programs and skews the TGF-β-induced differentiation into a Th1-like direction. Immunobiology. 2012;217:74–82. [DOI] [PubMed]

36.

Wang X, Lin Y. Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin. 2008;29:1275–88. [DOI] [PubMed] [PMC]

37.

Wack A, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16:802–9. [DOI] [PubMed] [PMC]

38.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11. [DOI]

39.

Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A. 1998;95:7556–61. [DOI] [PubMed] [PMC]

40.

Street SE, Trapani JA, MacGregor D, Smyth MJ. Suppression of lymphoma and epithelial malignancies effected by interferon γ. J Exp Med. 2002;196:129–34. [DOI] [PubMed] [PMC]

41.

Wang L, Wang Y, Song Z, Chu J, Qu X. Deficiency of interferon-gamma or its receptor promotes colorectal cancer development. J Interferon Cytokine Res. 2015;35:273–80. [DOI] [PubMed]

42.

Erick TK, Brossay L. Phenotype and functions of conventional and non-conventional NK cells. Curr Opin Immunol. 2016;38:67–74. [DOI] [PubMed] [PMC]

43.

Bhat P, Leggatt G, Waterhouse N, Frazer IH. Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 2017;8:e2836. [DOI] [PubMed] [PMC]

44.

Weizman OE, Adams NM, Schuster IS, Krishna C, Pritykin Y, Lau C, et al. ILC1 confer early host protection at initial sites of viral infection. Cell. 2017;171:795–808.E12. [DOI] [PubMed] [PMC]

45.

Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 2018;18:545–58. [DOI] [PubMed] [PMC]

46.

Kotredes KP, Gamero AM. Interferons as inducers of apoptosis in malignant cells. J Interferon Cytokine Res. 2013;33:162–70. [DOI] [PubMed] [PMC]

47.

Su Q, Wang F, Dong Z, Chen M, Cao R. IFN‑γ induces apoptosis in human melanocytes by activating the JAK1/STAT1 signaling pathway. Mol Med Rep. 2020;22:3111–6. [DOI] [PubMed] [PMC]

48.

Rakshit S, Chandrasekar BS, Saha B, Victor ES, Majumdar S, Nandi D. Interferon-gamma induced cell death: regulation and contributions of nitric oxide, cJun N-terminal kinase, reactive oxygen species and peroxynitrite. Biochim Biophys Acta. 2014;1843:2645–61. [DOI] [PubMed]

49.

Su X, Yu Y, Zhong Y, Giannopoulou EG, Hu X, Liu H, et al. Interferon-γ regulates cellular metabolism and mRNA translation to potentiate macrophage activation. Nat Immunol. 2015;16:838–49. [DOI] [PubMed] [PMC]

50.

Zhang C, Hou D, Wei H, Zhao M, Yang L, Liu Q, et al. Lack of interferon-γ receptor results in a microenvironment favorable for intestinal tumorigenesis. Oncotarget. 2016;7:42099–109. [DOI] [PubMed] [PMC]

51.

Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–66. [DOI] [PubMed]

52.

Heimes AS, Härtner F, Almstedt K, Krajnak S, Lebrecht A, Battista MJ, et al. Prognostic significance of interferon-γ and its signaling pathway in early breast cancer depends on the molecular subtypes. Int J Mol Sci. 2020;21:7178. [DOI] [PubMed] [PMC]

53.

Lee IC, Huang YH, Chau GY, Huo TI, Su CW, Wu JC, et al. Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments. Int J Cancer. 2013;133:2895–902. [DOI] [PubMed]

54.

Duncan TJ, Rolland P, Deen S, Scott IV, Liu DT, Spendlove I, et al. Loss of IFNγ receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res. 2007;13:4139–45. [DOI]

55.

Atri C, Guerfali FZ, Laouini D. Role of human macrophage polarization in inflammation during infectious diseases. Int J Mol Sci. 2018;19:1801. [DOI] [PubMed] [PMC]

56.

Pan Y, Yu Y, Wang X, Zhang T. Tumor-associated macrophages in tumor immunity. Front Immunol. 2020;11:583084. Erratum in: Front Immunol. 2021;12:775758. [DOI] [PubMed] [PMC]

57.

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677–86. [DOI] [PubMed]

58.

Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage M1–M2 polarization balance. Front Immunol. 2014;5:614. [DOI] [PubMed] [PMC]

59.

Nakanishi Y, Nakatsuji M, Seno H, Ishizu S, Akitake-Kawano R, Kanda K, et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in Apc ^Min^/+ mouse polyps. Carcinogenesis. 2011;32:1333–9. [DOI] [PubMed]

60.

Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19. [DOI] [PubMed] [PMC]

61.

Jackute J, Zemaitis M, Pranys D, Sitkauskiene B, Miliauskas S, Vaitkiene S, et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 2018;19:3. [DOI] [PubMed] [PMC]

62.

Dong P, Ma L, Liu L, Zhao G, Zhang S, Dong L, et al. CD86⁺/CD206⁺, diametrically polarized tumor-associated macrophages, predict hepatocellular carcinoma patient prognosis. Int J Mol Sci. 2016;17:320. [DOI] [PubMed] [PMC]

63.

Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA. Science. 1994;265:106–9. [DOI]

64.

Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889–96. [DOI] [PubMed]

65.

Ylikoski E, Lund R, Kyläniemi M, Filén S, Kilpeläinen M, Savolainen J, et al. IL-12 up-regulates T-bet independently of IFN-γ in human CD4⁺ T cells. Eur J Immunol. 2005;35:3297–306. Erratum in: Eur J Immunol. 2006;36:1058. [DOI] [PubMed]

66.

Eickhoff S, Brewitz A, Gerner MY, Klauschen F, Komander K, Hemmi H, et al. Robust anti-viral immunity requires multiple distinct T cell-dendritic cell interactions. Cell. 2015;162:1322–37. [DOI] [PubMed] [PMC]

67.

Bachem A, Hartung E, Güttler S, Mora A, Zhou X, Hegemann A, et al. Expression of XCR1 characterizes the Batf3-dependent lineage of dendritic cells capable of antigen cross-presentation. Front Immunol. 2012;3:214. [DOI] [PubMed] [PMC]

68.

Martínez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21:5047–56. [DOI] [PubMed]

69.

McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and cancer. Annu Rev Immunol. 2019;37:457–95. [DOI] [PubMed]

70.

Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8⁺ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124:359–67. [DOI] [PubMed] [PMC]

71.

Zhuang X, Shi G, Hu X, Wang H, Sun W, Wu Y. Interferon-gamma inhibits aldehyde dehydrogenase^bright cancer stem cells in the 4T1 mouse model of breast cancer. Chin Med J (Engl). 2021;135:194–204. [DOI] [PubMed] [PMC]

72.

Brenner E, Schörg BF, Ahmetlić F, Wieder T, Hilke FJ, Simon N, et al. Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours. Nat Commun. 2020;11:1335. [DOI] [PubMed] [PMC]

73.

Sun T, Yang Y, Luo X, Cheng Y, Zhang M, Wang K, et al. Inhibition of tumor angiogenesis by interferon-γ by suppression of tumor-associated macrophage differentiation. Oncol Res. 2014;21:227–35. [DOI] [PubMed]

74.

Vignali DAA, Kuchroo VK. IL-12 family cytokines: immunological playmakers. Nat Immunol. 2012;13:722–8. [DOI] [PubMed] [PMC]

75.

Lu Z, Xu K, Wang X, Li Y, Li M. Interleukin 39: a new member of interleukin 12 family. Cent Eur J Immunol. 2020;45:214–7. [DOI] [PubMed] [PMC]

76.

Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets. 2012;11:159–68. [DOI] [PubMed]

77.

Liu K, Huang A, Nie J, Tan J, Xing S, Qu Y, et al. IL-35 regulates the function of immune cells in tumor microenvironment. Front Immunol. 2021;12:683332. [DOI] [PubMed] [PMC]

78.

Zheng H, Ban Y, Wei F, Ma X. Regulation of interleukin-12 production in antigen-presenting cells. Adv Exp Med Biol. 2016;941:117–38. [DOI] [PubMed]

79.

Lasek W, Zagożdżon R, Jakobisiak M. Interleukin 12: still a promising candidate for tumor immunotherapy? Cancer Immunol Immunother. 2014;63:419–35. [DOI] [PubMed] [PMC]

80.

Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, et al. Positive regulatory role of IL-12 in macrophages and modulation by IFN-γ¹. J Immunol. 2001;167:221–7. [DOI] [PubMed]

81.

Meeran SM, Mantena SK, Meleth S, Elmets CA, Katiyar SK. Interleukin-12-deficient mice are at greater risk of UV radiation–induced skin tumors and malignant transformation of papillomas to carcinomas. Mol Cancer Ther. 2006;5:825–32. [DOI] [PubMed]

82.

Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent¹. J Immunol. 2000;165:2665–70. [DOI] [PubMed]

83.

Cohen CA, Shea AA, Heffron CL, Schmelz EM, Roberts PC. Interleukin-12 immunomodulation delays the onset of lethal peritoneal disease of ovarian cancer. J Interferon Cytokine Res. 2016;36:62–73. [DOI] [PubMed] [PMC]

84.

Zilocchi C, Stoppacciaro A, Chiodoni C, Parenza M, Terrazzini N, Colombo MP. Interferon γ-independent rejection of interleukin 12-transduced carcinoma cells requires CD4⁺ T cells and granulocyte/macrophage colony-stimulating factor. J Exp Med. 1998;188:133–43. [DOI] [PubMed] [PMC]

85.

Kaarvatn MH, Vrbanec J, Kulic A, Knezevic J, Petricevic B, Balen S, et al. Single nucleotide polymorphism in the interleukin 12B gene is associated with risk for breast cancer development. Scand J Immunol. 2012;76:329–35. [DOI] [PubMed]

86.

Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, et al. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 2009;15:400–5. [DOI] [PubMed]

87.

Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666–70. [DOI] [PubMed] [PMC]

88.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, et al. Tumor immune evasion arises through loss of TNF sensitivity. Sci Immunol. 2018;3:eaar3451. [DOI] [PubMed]

89.

Rath PC, Aggarwal BB. TNF-induced signaling in apoptosis. J Clin Immunol. 1999;19:350–64. [DOI] [PubMed]

90.

Idriss HT, Naismith JH. TNFα and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech. 2000;50:184–95. [DOI] [PubMed]

91.

Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med. 1999;5:828–31. Erratum in: Nat Med. 1999;5:1087. [DOI] [PubMed]

92.

Mercogliano MF, Bruni S, Elizalde PV, Schillaci R. Tumor necrosis factor α blockade: an opportunity to tackle breast cancer. Front Oncol. 2020;10:584. [DOI] [PubMed] [PMC]

93.

Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest. 1993;91:2194–206. [DOI] [PubMed] [PMC]

94.

Liu W, Lu X, Shi P, Yang G, Zhou Z, Li W, et al. TNF-α increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-κB pathway. Sci Rep. 2020;10:1804. [DOI] [PubMed] [PMC]

95.

Storci G, Sansone P, Mari S, D’Uva G, Tavolari S, Guarnieri T, et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol. 2010;225:682–91. [DOI] [PubMed] [PMC]

96.

Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490:412–6. [DOI] [PubMed]

97.

Salomon BL, Leclerc M, Tosello J, Ronin E, Piaggio E, Cohen JL. Tumor necrosis factor α and regulatory T cells in oncoimmunology. Front Immunol. 2018;9:444. [DOI] [PubMed] [PMC]

98.

Yao B, Wang L, Wang H, Bao J, Li Q, Yu F, et al. Seven interferon gamma response genes serve as a prognostic risk signature that correlates with immune infiltration in lung adenocarcinoma. Aging (Albany NY). 2021;13:11381–410. [DOI] [PubMed] [PMC]

99.

Tao Y, Tao T, Gross N, Peng X, Li Y, Huang Z, et al. Combined effect of IL-12Rβ2 and IL-23R expression on prognosis of patients with laryngeal cancer. Cell Physiol Biochem. 2018;50:1041–54. [DOI] [PubMed]

100.

Xu L, Pelosof L, Wang R, McFarland HI, Wu WW, Phue JN, et al. NGS evaluation of colorectal cancer reveals interferon gamma dependent expression of immune checkpoint genes and identification of novel IFNγ induced genes. Front Immunol. 2020;11:224. [DOI] [PubMed] [PMC]

101.

Korentzelos D, Wells A, Clark AM. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer. Scientific Reports. 2022;12:6657. [DOI] [PubMed] [PMC]

102.

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8:38022–43. [DOI] [PubMed] [PMC]

103.

Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138–44. [DOI] [PubMed] [PMC]

104.

Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, et al. A phase II study of GM-CSF and rIFN-γ1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol. 2009;113:210–5. [DOI] [PubMed] [PMC]

105.

Jorgovanovic D, Song M, Wang L, Zhang Y. Roles of IFN-γ in tumor progression and regression: a review. Biomark Res. 2020;8:49. [DOI] [PubMed] [PMC]

106.

Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, et al. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020;8:e000247. [DOI] [PubMed] [PMC]

107.

Grasso CS, Tsoi J, Onyshchenko M, Abril-Rodriguez G, Ross-Macdonald P, Wind-Rotolo M, et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 2020;38:500–15.E3. Erratum in: Cancer Cell. 2021;39:122. [DOI] [PubMed] [PMC]

108.

Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers (Basel). 2021;13:167. [DOI] [PubMed] [PMC]

109.

Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, et al. Effects of single-dose interleukin-12 exposure on interleukin-12–associated toxicity and interferon-γ production. Blood. 1997;90:2541–8. [PubMed]

110.

Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015;21:2278–88. [DOI] [PubMed] [PMC]

111.

Li J, Lin W, Chen H, Xu Z, Ye Y, Chen M. Dual-target IL-12-containing nanoparticles enhance T cell functions for cancer immunotherapy. Cell Immunol. 2020;349:104042. [DOI] [PubMed]

112.

Wang P, Li X, Wang J, Gao D, Li Y, Li H, et al. Re-designing interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun. 2017;8:1395. Erratum in: Nat Commun. 2018;9:203. [DOI] [PubMed] [PMC]

113.

Tucker CG, Mitchell JS, Martinov T, Burbach BJ, Beura LK, Wilson JC, et al. Adoptive T cell therapy with IL-12-preconditioned low-avidity T cells prevents exhaustion and results in enhanced T cell activation, enhanced tumor clearance, and decreased risk for autoimmunity. J Immunol. 2020;205:1449–60. [DOI] [PubMed] [PMC]

114.

Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, et al. Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol. 2013;133:545–52. [DOI] [PubMed]

115.

Greiner JW, Morillon YM 2nd, Schlom J. NHS-IL12, a tumor-targeting immunocytokine. Immunotargets Ther. 2021;10:155–69. [DOI] [PubMed] [PMC]

116.

Wu X, Wu MY, Jiang M, Zhi Q, Bian X, Xu MD, et al. TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells. Cancer Cell Int. 2017;17:13. [DOI] [PubMed] [PMC]

117.

Roberts NJ, Zhou S, Diaz LA Jr, Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget. 2011;2:739–51. [DOI] [PubMed] [PMC]

118.

Creaven PJ, Plager JE, Dupere S, Huben RP, Takita H, Mittelman A, et al. Phase I clinical trial of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol. 1987;20:137–44. [DOI] [PubMed]

119.

Budd GT, Green S, Baker LH, Hersh EP, Weick JK, Osborne CK. A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer. Cancer. 1991;68:1694–5. Erratum in: Cancer. 1992;69:2866. [DOI] [PubMed]

120.

Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 2015;350:981–5. [DOI] [PubMed] [PMC]

121.

Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TKA, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010;464:1367–70. [DOI] [PubMed] [PMC]

122.

Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4⁺ T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014;41:283–95. [DOI] [PubMed] [PMC]

123.

McLeod JJ, Baker B, Ryan JJ. Mast cell production and response to IL-4 and IL-13. Cytokine. 2015;75:57–61. [DOI] [PubMed] [PMC]

124.

Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in asthma and other eosinophilic disorders. Front Med (Lausanne). 2017;4:139. [DOI] [PubMed] [PMC]

125.

Piehler D, Stenzel W, Grahnert A, Held J, Richter L, Köhler G, et al. Eosinophils contribute to IL-4 production and shape the T-helper cytokine profile and inflammatory response in pulmonary cryptococcosis. Am J Pathol. 2011;179:733–44. [DOI] [PubMed] [PMC]

126.

Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, et al. Transforming growth factor-β ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol. 2008;9:1341–6. [DOI] [PubMed]

127.

Forbes E, van Panhuys N, Min B, Le Gros G. Differential requirements for IL-4/STAT6 signalling in CD4 T-cell fate determination and Th2-immune effector responses. Immunol Cell Biol. 2010;88:240–3. [DOI] [PubMed]

128.

Junttila IS. Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;9:888. [DOI] [PubMed] [PMC]

129.

Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713–6. [DOI] [PubMed]

130.

Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989;57:503–12. [DOI] [PubMed]

131.

Stoppacciaro A, Paglia P, Lombardi L, Parmiani G, Baroni C, Colombo MP. Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol. 1997;27:2375–82. [DOI] [PubMed]

132.

Osawa E, Nakajima A, Fujisawa T, Kawamura YI, Toyama-Sorimachi N, Nakagama H, et al. Predominant T helper type 2-inflammatory responses promote murine colon cancers. Int J Cancer. 2006;118:2232–6. [DOI] [PubMed]

133.

Jayakumar A, Bothwell ALM. Stat6 promotes intestinal tumorigenesis in a mouse model of adenomatous polyposis by expansion of MDSCs and inhibition of cytotoxic CD8 response. Neoplasia. 2017;19:595–605. [DOI] [PubMed] [PMC]

134.

McClellan JL, Steiner JL, Day SD, Enos RT, Davis MJ, Singh UP, et al. Exercise effects on polyp burden and immune markers in the ApcMin/+ mouse model of intestinal tumorigenesis. Int J Oncol. 2014;45:861–8. [DOI] [PubMed] [PMC]

135.

Li Z, Jiang J, Wang Z, Zhang J, Xiao M, Wang C, et al. Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis. Cancer Res. 2008;68:8687–94. [DOI] [PubMed]

136.

Nappo G, Handle F, Santer FR, McNeill RV, Seed RI, Collins AT, et al. The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis. 2017;6:e342. [DOI] [PubMed] [PMC]

137.

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, et al. ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127:2916–29. [DOI] [PubMed] [PMC]

138.

Shi J, Song X, Traub B, Luxenhofer M, Kornmann M. Involvement of IL-4, IL-13 and their receptors in pancreatic cancer. Int J Mol Sci. 2021;22:2998. [DOI] [PubMed] [PMC]

139.

Suzuki A, Leland P, Joshi BH, Puri RK. Targeting of IL-4 and IL-13 receptors for cancer therapy. Cytokine. 2015;75:79–88. [DOI] [PubMed]

140.

Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK. Recent advances in IL-13Rα2-directed cancer immunotherapy. Front Immunol. 2022;13:878365. [DOI] [PubMed] [PMC]

141.

Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophils in the pathogenesis of asthma. Allergy Asthma Immunol Res. 2012;4:68–79. [DOI] [PubMed] [PMC]

142.

Mori Y, Iwasaki H, Kohno K, Yoshimoto G, Kikushige Y, Okeda A, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009;206:183–93. [DOI] [PubMed] [PMC]

143.

Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008;20:288–94. [DOI] [PubMed]

144.

Zaynagetdinov R, Sherrill TP, Gleaves LA, McLoed AG, Saxon JA, Habermann AC, et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75:1624–34. [DOI] [PubMed] [PMC]

145.

Gatault S, Delbeke M, Driss V, Sarazin A, Dendooven A, Kahn JE, et al. IL-18 is involved in eosinophil-mediated tumoricidal activity against a colon carcinoma cell line by upregulating LFA-1 and ICAM-1. J Immunol. 2015;195:2483–92. [DOI] [PubMed]

146.

Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hämmerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8⁺ T cells. Nat Immunol. 2015;16:609–17. Erratum in: Nat Immunol. 2016;176:214. [DOI] [PubMed]

147.

Prizment AE, Anderson KE, Visvanathan K, Folsom AR. Inverse association of eosinophil count with colorectal cancer incidence: atherosclerosis risk in communities study. Cancer Epidemiol Biomarkers Prev. 2011;20:1861–4. [DOI] [PubMed] [PMC]

148.

Harbaum L, Pollheimer MJ, Kornprat P, Lindtner RA, Bokemeyer C, Langner C. Peritumoral eosinophils predict recurrence in colorectal cancer. Mod Pathol. 2015;28:403–13. [DOI] [PubMed]

149.

Onesti CE, Josse C, Boulet D, Thiry J, Beaumecker B, Bours V, et al. Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. 2020;9:1761176. [DOI] [PubMed] [PMC]

150.

Moreira A, Leisgang W, Schuler G, Heinzerling L. Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy. 2017;9:115–21. [DOI] [PubMed]

151.

Schuijs MJ, Png S, Richard AC, Tsyben A, Hamm G, Stockis J, et al. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung. Nat Immunol. 2020;21:998–1009. [DOI] [PubMed] [PMC]

152.

van Driel WJ, Kievit-Tyson P, van den Broek LC, Zwinderman AH, Trimbos BJ, Fleuren GJ. Presence of an eosinophilic infiltrate in cervical squamous carcinoma results from a type 2 immune response. Gynecol Oncol. 1999;74:188–95. [DOI] [PubMed]

153.

Pinto A, Aldinucci D, Gloghini A, Zagonel V, Degan M, Perin V, et al. The role of eosinophils in the pathobiology of Hodgkin’s disease. Ann Oncol. 1997;8:S89–96. [PubMed]

154.

Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res. 2007;31:915–20. [DOI] [PubMed]

155.

Cai L, Zhang Y, Zhang Y, Chen H, Hu J. Effect of Th9/IL-9 on the growth of gastric cancer in nude mice. Onco Targets Ther. 2019;12:2225–34. [DOI] [PubMed] [PMC]

156.

Wan J, Wu Y, Huang L, Tian Y, Ji X, Abdelaziz MH, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8⁺ T cells. Cancer Lett. 2021;502:34–43. [DOI] [PubMed]

157.

Parrot T, Allard M, Oger R, Benlalam H, Raingeard de la Blétière D, Coutolleau A, et al. IL-9 promotes the survival and function of human melanoma-infiltrating CD4⁺CD8⁺ double-positive T cells. Eur J Immunol. 2016;46:1770–82. [DOI] [PubMed]

158.

Do Thi VA, Park SM, Lee H, Kim YS. Ectopically expressed membrane-bound form of IL-9 exerts immune-stimulatory effect on CT26 colon carcinoma cells. Immune Netw. 2018;18:e12. [DOI] [PubMed] [PMC]

159.

Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ. Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges. Cancer Res. 2014;74:6845–55. [DOI] [PubMed] [PMC]

160.

Goswami R, Kaplan MH. A brief history of IL-9. J Immunol. 2011;186:3283–8. [DOI] [PubMed] [PMC]

161.

Ribatti D, Ennas MG, Vacca A, Ferreli F, Nico B, Orru S, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003;33:420–5. [DOI] [PubMed]

162.

Nonomura N, Takayama H, Nishimura K, Oka D, Nakai Y, Shiba M, et al. Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. Br J Cancer. 2007;97:952–6. [DOI] [PubMed] [PMC]

163.

Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, et al. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res. 2010;16:2257–65. [DOI] [PubMed] [PMC]

164.

Blair RJ, Meng H, Marchese MJ, Ren S, Schwartz LB, Tonnesen MG, et al. Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor. J Clin Invest. 1997;99:2691–700. [DOI] [PubMed] [PMC]

165.

Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more potent than IL-25 in provoking IL-13–producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol. 2013;132:933–41. [DOI] [PubMed]

166.

Roan F, Obata-Ninomiya K, Ziegler SF. Epithelial cell–derived cytokines: more than just signaling the alarm. J Clin Invest. 2019;129:1441–51. [DOI] [PubMed] [PMC]

167.

Ricardo-Gonzalez RR, Van Dyken SJ, Schneider C, Lee J, Nussbaum JC, Liang HE, et al. Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol. 2018;19:1093–9. [DOI] [PubMed] [PMC]

168.

Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both T_h1- and T_h2-type responses through its activity on human basophils, allergen-reactive T_h2 cells, iNKT and NK cells. Int Immunol. 2008;20:1019–30. [DOI] [PubMed]

169.

Cho KA, Suh JW, Sohn JH, Park JW, Lee H, Kang JL, et al. IL-33 induces Th17-mediated airway inflammation via mast cells in ovalbumin-challenged mice. Am J Physiol Lung Cell Mol Physiol. 2012;302:L429–40. [DOI] [PubMed]

170.

Schiering C, Krausgruber T, Chomka A, Fröhlich A, Adelmann K, Wohlfert EA, et al. The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature. 2014;513:564–8. [DOI] [PubMed] [PMC]

171.

Pascual-Reguant A, Bayat Sarmadi J, Baumann C, Noster R, Cirera-Salinas D, Curato C, et al. T_H17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine. Mucosal Immunol. 2017;10:1431–42. [DOI] [PubMed]

172.

Liu J, Qian B, Zhou L, Shen G, Tan Y, Liu S, et al. IL25 enhanced colitis-associated tumorigenesis in mice by upregulating transcription factor GLI1. Front Immunol. 2022;13:837262. [DOI] [PubMed] [PMC]

173.

Goto N, Fukuda A, Yamaga Y, Yoshikawa T, Maruno T, Maekawa H, et al. Lineage tracing and targeting of IL17RB⁺ tuft cell-like human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2019;116:12996–3005. [DOI] [PubMed] [PMC]

174.

Benatar T, Cao MY, Lee Y, Lightfoot J, Feng N, Gu X, et al. IL-17E, a proinflammatory cytokine, has antitumor efficacy against several tumor types in vivo. Cancer Immunol Immunother. 2010;59:805–17. [DOI] [PubMed]

175.

Furuta S, Jeng YM, Zhou L, Huang L, Kuhn I, Bissell MJ, et al. IL-25 causes apoptosis of IL-25R–expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med. 2011;3:78ra31. [DOI] [PubMed] [PMC]

176.

Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, Arsenijevic N, et al. ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol. 2011;41:1902–12. [DOI] [PubMed] [PMC]

177.

Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer. 2014;134:1669–82. [DOI] [PubMed]

178.

Shin N, Son GM, Shin DH, Kwon MS, Park BS, Kim HS, et al. Cancer-associated fibroblasts and desmoplastic reactions related to cancer invasiveness in patients with colorectal cancer. Ann Coloproctol. 2019;35:36–46. [DOI] [PubMed] [PMC]

179.

Milosavljevic MZ, Jovanovic IP, Pejnovic NN, Mitrovic SLJ, Arsenijevic NN, Simovic Markovic BJ, et al. Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma. Oncotarget. 2016;7:18106–15. [DOI] [PubMed] [PMC]

180.

Corrigan CJ, Wang W, Meng Q, Fang C, Wu H, Reay V, et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A. 2011;108:1579–84. [DOI] [PubMed] [PMC]

181.

Yao X, Wang W, Li Y, Huang P, Zhang Q, Wang J, et al. IL-25 induces airways angiogenesis and expression of multiple angiogenic factors in a murine asthma model. Respir Res. 2015;16:39. [DOI] [PubMed] [PMC]

182.

Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A. 2015;112:E2487–96. [DOI] [PubMed] [PMC]

183.

He Z, Chen L, Souto FO, Canasto-Chibuque C, Bongers G, Deshpande M, et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in Apc ^Min/+ mice. Sci Rep. 2017;7:5520. [DOI] [PubMed] [PMC]

184.

Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19:57–64. [DOI] [PubMed]

185.

Kang C, Jeong SY, Song SY, Choi EK. The emerging role of myeloid-derived suppressor cells in radiotherapy. Radiat Oncol J. 2020;38:1–10. [DOI] [PubMed] [PMC]

186.

Kawano M, Mabuchi S, Matsumoto Y, Sasano T, Takahashi R, Kuroda H, et al. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep. 2015;5:18217. [DOI] [PubMed] [PMC]

187.

Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35:559–72.E7. [DOI] [PubMed] [PMC]

188.

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol. 2018;9:1310. [DOI] [PubMed] [PMC]

189.

Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, et al. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy. Clin Cancer Res. 2002;8:3503–11. [PubMed]

190.

Guo C, Ouyang Y, Cai J, Xiong L, Chen Y, Zeng X, et al. High expression of IL-4R enhances proliferation and invasion of hepatocellular carcinoma cells. Int J Biol Markers. 2017;32:e384–90. [DOI] [PubMed]

191.

Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol. 1994;5:447–52. [DOI] [PubMed]

192.

Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J Immunother. 2002;25:352–8. [DOI] [PubMed]

193.

Whitehead RP, Unger JM, Goodwin JW, Walker MJ, Thompson JA, Flaherty LE, et al. Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group study. J Immunother. 1998;21:440–6. [DOI] [PubMed]

194.

Margolin K, Aronson FR, Sznol M, Atkins MB, Gucalp R, Fisher RI, et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol. 1994;15:147–53. [DOI] [PubMed]

195.

Tong H, Feng H, Hu X, Wang MF, Song YF, Wen XL, et al. Identification of interleukin-9 producing immune cells in endometrial carcinoma and establishment of a prognostic nomogram. Front Immunol. 2020;11:544248. [DOI] [PubMed] [PMC]

196.

Heim L, Yang Z, Tausche P, Hohenberger K, Chiriac MT, Koelle J, et al. IL-9 producing tumor-infiltrating lymphocytes and Treg subsets drive immune escape of tumor cells in non-small cell lung cancer. Front Immunol. 2022;13:859738. [DOI] [PubMed] [PMC]

197.

Eiró N, González L, González LO, Fernandez-Garcia B, Lamelas ML, Marín L, et al. Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One. 2012;7:e49047. [DOI] [PubMed] [PMC]

198.

Blomberg OS, Spagnuolo L, Garner H, Voorwerk L, Isaeva OI, van Dyk E, et al. IL-5-producing CD4⁺ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell. 2023;41:106–23.E10. [DOI] [PubMed]

199.

Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, et al. Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26:31–44. [DOI] [PubMed] [PMC]

200.

Zeng J, Zhang J, Yang YZ, Wang F, Jiang H, Chen HD, et al. IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients. Am J Transl Res. 2020;12:4702–14. [PubMed] [PMC]

201.

Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3:436–43. [DOI] [PubMed] [PMC]

202.

Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8:1142–8. [DOI] [PubMed] [PMC]